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Ebf factors and MyoD cooperate to regulate
muscle relaxation via Atp2a1
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Myogenic regulatory factors such as MyoD and Myf5 lie at the core of vertebrate muscle
differentiation. However, E-boxes, the cognate binding sites for these transcription factors, are
not restricted to the promoters/enhancers of muscle cell-speciﬁc genes. Thus, the speciﬁcity
in myogenic transcription is poorly deﬁned. Here we describe the transcription factor Ebf3 as
a new determinant of muscle cell-speciﬁc transcription. In the absence of Ebf3 the lung does
not unfold at birth, resulting in respiratory failure and perinatal death. This is due to a
hypercontractile diaphragm with impaired Ca2þ efﬂux-related muscle functions. Expression
of the Ca2þ pump Serca1 (Atp2a1) is downregulated in the absence of Ebf3, and its
transgenic expression rescues this phenotype. Ebf3 binds directly to the promoter of Atp2a1
and synergises with MyoD in the induction of Atp2a1. In skeletal muscle, the homologous
family member Ebf1 is strongly expressed and together with MyoD induces Atp2a1. Thus, Ebf3
is a new regulator of terminal muscle differentiation in the diaphragm, and Ebf factors
cooperate with MyoD in the induction of muscle-speciﬁc genes.
DOI: 10.1038/ncomms4793
1 Institute of Clinical Molecular Biology and Tumor Genetics, Helmholtz Zentrum Mu¨nchen, National Research Center for Environmental Health,
Marchioninistrasse 25, 81377 Munich, Germany. 2 Institute of Pathology, Helmholtz Zentrum Mu¨nchen, National Research Center for Environmental Health,
Ingolsta¨dter Landstr. 1, 85764 Neuherberg, 81377 Munich, Germany. 3 Developmental Biology Section, Ecole Normale Supe´rieure, Rue d’Ulm 46, 75230 Paris,
France. 4 Stem Cells Department, CABIMER (CISC), Av Ame´rico Vespucio, 41092 Sevilla, Spain. 5Medical Biophysics Unit, Institute of Physiology and
Pathophysiology, University of Heidelberg, Im Neuenheimer Feld 326, 69120 Heidelberg, Germany. 6 Institute of Pathology, Technische Universita¨t Mu¨nchen,
Ismaningerstrasse 22, 81675 Munich, Germany. 7 Division of Endocrinology, Diabetes and Metabolic Bone Diseases, Department of Medicine III, TU Dresden
Medical Center, Fetscherstrasse 74, 01307 Dresden, Germany. Correspondence and requests for materials should be addressed to M.K.
(email: matthias.kieslinger@helmholtz-muenchen.de).
NATURE COMMUNICATIONS | 5:3793 | DOI: 10.1038/ncomms4793 | www.nature.com/naturecommunications 1
& 2014 Macmillan Publishers Limited. All rights reserved.
M
uscle cells in the body of vertebrates specify and
differentiate from mesenchymal progenitor cells in the
somites1. This process is initiated by the combined
action of the transcription factors Pax3 and Pax7 (ref. 2).
Together with the myogenic regulatory factors (MRF) Myf5 and
MyoD they form a regulatory network that is central to all early
muscle cell differentiation3,4. Once immature myoblasts have
formed, they fuse to generate multinucleated mature muscle cells
or myotubes, which constitute the minimal functional unit of all
muscles in the body. The transcription factors Myogenin and
Mrf4 regulate the later steps of differentiation by inﬂuencing the
expression of muscle-speciﬁc genes encoding contractile proteins
in fast and slow twitch ﬁbres4. Contraction of skeletal muscles is
achieved via the inﬂux of Ca2þ into the cytosol and its
interaction with Troponin C, triggering the ATP-dependent
sliding of a-actin and myosin ﬁlaments along each other.
For relaxation, Ca2þ is actively removed from the cytosol
into the sarcoplasmic reticulum by Serca proteins, which are
ATP-dependent Ca2þ -speciﬁc ion pumps5,6.
All MRF proteins bind to E-box sequences that are present in
the enhancers or promoters of genes coding for most muscle
contractile proteins4 and also a great many that are not
related to muscle-speciﬁc genes7. Genome-wide Chromatin
immunoprecipitation (ChIP)-seq analysis revealed that MyoD
binds to a large number of E-boxes including non muscle-speciﬁc
ones8. Therefore, additional transcription factors are required to
regulate MRF speciﬁcity for particular target genes. Mef2 is such
an example, as it binds to sites often present in contractile protein
enhancers and interacts cooperatively with MRFs9,10.
Among the skeletal muscles, the diaphragm is one of the most
essential ones, separating the pleural and abdominal body
cavities. It consists of two different muscles, the crural muscle,
which has a central and dorsal location surrounding the
oesophagus and aorta, and the costal muscle, which connects
the diaphragm’s central tendon to the surrounding ribs. During
embryonic development, muscle progenitor cells migrate from
cervical somites to the pleuroperitoneal folds, transient structures
surrounding the oesophagus11. These are assumed to fuse with
the septum transversum, which is thought to give rise to
the central tendon. Many important aspects of diaphragm
development are still unclear, despite its requirement for the
unfolding of the lung at birth and subsequent respiration12.
The family of early B cell factor (Ebf) genes encodes a highly
homologous group of transcription factors consisting of four
members in mammals. The proteins possess a N-terminal
DNA-binding domain, which also harbours transactivation
potential, followed by an IPT/TIG (immunoglobulin, plexins,
transcription factors-like/transcription factor immunoglobulin)
domain, presumably mediating protein–protein interaction, and
an atypical helix-loop-helix domain required for the formation of
homo- and heterodimers. A transactivation domain (TAD) at the
C terminus mediates activation of Ebf target genes13,14. As all
four proteins share over 90% sequence homology within these
domains, except for the TAD, all Ebf proteins bind to the same
DNA sequence and can act redundantly15–17.
Ebf3 is a member of this protein family that is poorly
characterized compared with other Ebf factors. Originally
identiﬁed in neuronal cells18,19, Ebf3 is important for cell
migration in the developing cortex17 and in the projection of
olfactory neurons to the olfactory bulb16. In Xenopus the
homologue Xebf3 acts as a regulator of neuronal differentiation
downstream of XNeuroD20. Furthermore, Ebf3 has been
implicated as a negative regulator of cell proliferation21. Ectopic
expression suppresses proliferation and induces apoptosis of
tumour cell lines22 and Ebf3 was found to be silenced in
most high-grade brain tumour cases in a genome-wide screen
for tumour suppressors23. Silencing of Ebf3 via promoter
methylation was also observed in gastric cancer, and ectopic
expression induced cell cycle arrest and apoptosis24.
Here, we present evidence that mammalian muscle cells
express Ebf3. Its function is critical in the relaxation of muscle
ﬁbres of the diaphragm and essential to allow respiration
immediately after birth preventing postnatal lethality. Ebf3
synergises with MyoD in directly regulating the expression of a
Ca2þ pump necessary for muscle relaxation. Thereby, Ebf3 is a
new transcription factor involved in the regulation of muscle cell-
speciﬁc transcription.
Results
Expression of Ebf3. To analyse the biological role of Ebf3, we
disrupted its gene locus in murine ES cells. Therefore, a targeting
vector was constructed in which an NLS-lacZ gene and a
PGK::neo cassette, ﬂanked by loxP sites, were cloned in frame
after the translational start codon of Ebf3, replacing the ﬁrst four
exons of Ebf3 (Supplementary Fig. 1A). These exons (represent-
ing the ﬁrst 138 amino acids) encode for essential parts of the
DNA-binding and transactivation domain of Ebf3 (ref. 19). Two
out of 800 clones of mouse embryonic stem cells analysed had
correctly incorporated the targeting construction (clones #1 and
#2; Supplementary Fig. 1B). Analysis of genomic DNA from
E18.5 embryos from heterozygous matings by PCR revealed the
presence of all three possible genotypes (Supplementary Fig. 1C;
primers indicated in Supplementary Fig. 1A). To conﬁrm the
disruption of Ebf3 independently of the genomic status,
semiquantitative RT–PCR was performed, revealing the loss of
the Ebf3 transcript in bones of embryonic day (E)18.5 embryos
(Supplementary Fig. 1D).
As a ﬁrst step in the biological analysis of Ebf3, we determined
its expression during embryonic development. Initial but low
expression of Ebf3 can be detected in the second branchial arch
around E8.5 (Supplementary Fig. 3A). Although somites are
present at this stage, Ebf3 is expressed in these structures only
later, at around E9.0 (Supplementary Fig. 3B). In the following
stages, the expression of Ebf3 becomes more complex with
prominent sites in the midbrain, the branchial arches, the dorsal
root ganglia and the olfactory epithelium (Supplementary Fig. 2).
To analyse the expression of Ebf3 independently, qPCR was
performed on whole wild-type embryos between E7.5 and E18.5
(Supplementary Fig. 3C). In this approach, Ebf3 is ﬁrst detectable
at E9.5, strongly increases at E10.5, and is present throughout
embryonic development thereafter with a pronounced decrease at
E15.5 and E16.5. These results conﬁrm data from EST databases,
which list Ebf3 expression from E9.5 on, and are also in line with
the b-gal staining shown here, with the only exception that the
very ﬁrst expression was probably below the detection limit in the
settings used for qPCR. Furthermore, the data show that the loss
of Ebf3 does not alter overall morphology during embryonic
development (Fig. 1a–c and Supplementary Fig. 2). A more
detailed analysis of tissues and cells in E16.5 embryos reveals
prominent expression of Ebf3 in neuronal structures such as the
midbrain, the cerebellar primordium and the mantle layer of
the spinal cord (Fig. 1b). Strong expression is also observed
in the olfactory epithelium, adipose tissue and at sites of
skeletogenesis such as ribs and vertebrae. Moreover, expression
is seen in developing skeletal muscle tissues like the diaphragm
and in the limbs. Again, no developmental defects were observed
in the absence of Ebf3 (Fig. 1c). Staining of E16.5 wild-type
embryos indicates the speciﬁcity of the observed signals except for
the inner lumen of the duodenum (Fig. 1a). To quantify the
expression of Ebf3 in various tissues, we isolated different organs
of E18.5 embryonic and 3-week-old wild-type mice and analysed
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them by qPCR. Accordingly Ebf3 shows the highest expression in
the diaphragm, followed by bone marrow, brain and skeletal
muscle in the embryo (Fig. 1g). Adult mice express Ebf3 at the
highest levels in skeletal muscle followed by the uterus, eye and
diaphragm. Intermediate expression levels can be detected in the
eye, testis, brain and lymph node, and low expression is seen
in the bone marrow and kidney. No expression of Ebf3 was
detected in the lung, thymus, spleen, liver and heart (Fig. 1g).
As diaphragm showed the highest expression among all organs
and tissues examined, we analysed its expression in further details
using in situ detection of b-galactosidase activity. Ebf3 expression
delineates the diaphragm at E18.5, is expressed in the majority,
but not all cells (Fig. 1e), and is speciﬁc in comparison with wild
type (Fig. 1d). Deletion of one or both alleles of Ebf3 does
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Figure 1 | Expression of Ebf3 at sites of osteogenesis and muscle formation. (a–c) Staining for b-galactosidase in cryosections of E16.5 Ebf3þ /þ
(a), Ebf3þ / (b) and Ebf3 / (c) embryos. Ebf3-b-gal-positive cells can be detected in neuronal, olfactory and adipocytic tissues and at sites of
osteogenesis and muscle formation. Staining in the lumen of the duodenum is background. (d–f) Magniﬁcation of Ebf3-b-gal staining in the area
surrounding parts of the diaphragm in Ebf3þ /þ (d), Ebf3þ / (e) and Ebf3 / (f) embryos as indicated by black boxes in a–c. The diaphragm
in this magniﬁcation is surrounded by the lung and liver tissue as indicated. Bar, 100mm. (g) Quantitative PCR analysis of the expression of Ebf3 in
various tissues of wild-type E18.5 embryos (left) or adult animals (right). The pro-B cell line Ba/F3 was used as a negative control and set to 1. n¼ 3;
error bars¼ s.d. Signiﬁcance is calculated in comparison with BaF/3. **Po0.01, ***Po0.001. (h) Single-cell suspensions from the diaphragm of E18.5
Ebf3þ / embryos were sorted into Ebf3-b-gal-positive and -negative cells and subjected to expression analysis of the indicated marker genes for
slow (MyHC-Ib) and fast (MyHC-IIA, MyHC-IIB, MyHC-IIX/D) twitch muscle types by qPCR. n¼ 3; error bars¼ s.d., *Po0.05 **Po0.01.
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not change overall morphology, but seems to induce a slightly
thickened appearance of the diaphragm (Fig. 1f). The diaphragm
consists of B10% type I (slow twitch) and 90% type II (fast
twitch) ﬁbres, which can be distinguished by the expression of
different isoforms of the myosin heavy chain25,26. Ebf3 is strongly
enriched in cells expressing the type II-associated isoforms
MyHC-IIa, MyHC-IIB and MyHC-IIX/D, whereas the type
I-associated MyHC-Ib prevails in Ebf3-negative cells, indicating
that Ebf3 is preferentially expressed by type II or fast twitch ﬁbres
(Fig. 1h).
Deletion of Ebf3 leads to respiratory failure. Embryonic
development proceeds normally in the absence of Ebf3, and, to
deﬁne the biological role of Ebf3 postnatally, we evaluated gen-
otypes from offspring of heterozygous matings at various time
points after birth. From postnatal day 0.5 (D0.5) on, we could not
detect any Ebf3-deﬁcient mice (Fig. 2a), and therefore analysed
earlier time points observing a normal Mendelian ratio of wild
type, heterozygous and knock-out embryos at E18.5 (Fig. 2a).
This ﬁnding suggests lethality around birth, and indeed a close
observation of animals at birth revealed that pups were born alive,
and Ebf3 / mice were indistinguishable from wild-type and
heterozygous littermates in their overall appearance. However,
immediately after birth, Ebf3-deﬁcient mice displayed gasping
respiration and progressive cyanosis (Fig. 2b), and died within 0.5
to 2 h after birth. Examination of wild-type newborn mice showed
that the lungs are unfolded and have a normal appearance of
alveolar ductal lumens, alveoli and small pulmonary vessels
(Fig. 2c–e, upper row). In contrast, lungs from Ebf3 / mice
have a congested appearance, do not unfold, and in consequence
air-containing passages are not formed as in wild-type lungs
(Fig. 2c–e, lower row). This result suggests that the postnatal
lethality and the cyanotic appearance are very likely due to
respiratory failure caused by an inability to unfold the lung at
birth. However, it seems to be a secondary effect, as Ebf3 is not
expressed in the lung (Fig. 1a–g), the morphology of the compact
lung is normal (Fig. 2c–e, lower row) and unfolding is not a lung-
intrinsic property.
The diaphragm and the rib cage are necessary to support lung
function and breathing, and muscle cells of the diaphragm
strongly express Ebf3 (Fig. 1g). As osteoblastic cells express Ebf3
during in vitro differentiation27, we examined the expression of
Ebf3 in bone and bone marrow in vivo to elucidate its role in
skeletogenesis and bone formation. The bone marrow is a
complex mixture of various cell types, and haematopoietic cells
do not express Ebf3 as shown by Ebf3-b-gal staining
(Supplementary Fig. 5A) or by semiquantitative RT–PCR of
E18.5 fetal liver cells (Supplementary Fig. 5B). As primary
Ebf3-positive mesenchymal cells of the bone marrow express high
levels of Scleraxis, aP2 and Prx1, but no markers of chondrocytes
or mature osteoblasts (Supplementary Fig. 4A), we conclude that
Ebf3 is expressed by immature mesenchymal cells, including
mesenchymal stem cells, skeletal progenitors and adipocytes.
A slight increase in CFU-F numbers, that is, in the frequency of
immature mesenchymal cells of the bone marrow, was observed
(Supplementary Fig. 4B), but loss of Ebf3 has no effect on the
formation of bone and cartilage as exempliﬁed by Alcian blue/
Alizarin red staining of E18.5 embryos (Fig. 2f) or at various other
developmental stages (Supplementary Fig. 4C). In addition,
analysis of calciﬁed mineral bone by von Kossa staining
revealed no differences in the absence of Ebf3 (Supplementary
Fig. 4D). Furthermore, no defects in fetal haematopoiesis were
observed (Supplementary Fig. 5C). In contrast, thickening of
muscle ﬁbres was observed in the diaphragm of Ebf3 /
newborn mice, suggesting that deletion of Ebf3 might cause
defects in muscle function (Fig. 2g,h).
Defects in diaphragm contraction in absence of Ebf3. As the
diaphragm has a central role in facilitating the unfolding of the
lung and supporting breathing after birth28, we followed this
observation closer. Electron microscopy revealed hypercontracted
regions within the diaphragm in the absence of Ebf3 and a
shortening of Z-stacks (Fig. 3A,B). Within these regions,
sarcomere length was reduced 38% from 2.11 mm in wild-type
diaphragm to about 1.34 mm in Ebf3 / newborn mice
(Fig. 3C). The phenotype described so far indicates problems
with the relaxation of muscle cells in the absence of Ebf3. To
study potential defects in muscle function in more detail, we
isolated the diaphragm from Ebf3 wild-type and mutant newborn
animals and analysed their reaction to deﬁned electrical
stimulation. In a ﬁrst set of experiments the diaphragm was
electrically stimulated with a single pulse of 50V for 1ms.
Measurement of the resulting twitch shows that the force
produced by the Ebf3-deﬁcient diaphragm was reduced by a
factor of 18 compared with wild-type levels (Fig. 3D). The total
duration of the contraction in response to a single stimulation
was prolonged 11.6-fold (Fig. 3E). As muscle function normally
involves sustained activation, we also measured the same
parameters during tetanus stimulation of the isolated
diaphragm (50V, 1ms, 120Hz for 500ms; Supplementary
Fig. 6A,B). The force produced in response to tetanus
stimulation was reduced by a factor of 3.6 (Supplementary
Fig. 6A), conﬁrming data from the single stimulation
experiment. Furthermore, the full duration of the contraction
after tetanus stimulation was prolonged 23-fold (Supplementary
Fig. 6B). Taken together, the results indicate a strongly
reduced force produced by the diaphragm in response to
stimulation, which explains the missing expansion of the lung
in Ebf3-deﬁcient mice and the resulting failure of respiration and
cyanotic death. Furthermore, the fact that the muscle can be
stimulated, but the duration of the contraction is strongly
prolonged, suggests an impairment in muscle relaxation after
stimulation.
Ebf3 is required for expression of Atp2a1. To gain an under-
standing of the molecular mechanism behind this deﬁciency,
we analysed the expression of genes implicated in muscle con-
traction and relaxation in the diaphragm of E18.5 wild-type and
Ebf3-deﬁcient mice. The vast majority of these candidate genes
did not show differences in expression in absence of Ebf3
(Fig. 3F). A slight but signiﬁcant decrease was observed with
Mlc1f, Tnni2 and skeletal muscle-speciﬁc a-actin, which are all
required for contraction as well as relaxation. Interestingly, the
expression of Atp2a1, which encodes a sarcoplasmic reticulum
Ca2þ -ATPase required for muscle relaxation, was decreased by a
factor of B10, and Ebf3-deﬁcient mice display an almost exact
phenocopy of the deletion of the Atp2a1 gene29. As not all cells of
the diaphragm express Ebf3 (Fig. 1e,f), we sorted Ebf3-b-gal-
expressing cells from the diaphragm by ﬂow cytometry from
Ebf3þ / and Ebf3 / mice. In heterozygous cells Ebf3 was
detected almost exclusively in the b-gal-positive population,
showing a high level of puriﬁcation by this method (Fig. 3G).
Atp2a1 is a marker for fast twitch muscle cells and was strongly
enriched among the Ebf3-b-gal-positive cells in Ebf3þ /
animals, conﬁrming our previous ﬁnding that Ebf3-expressing
cells constitute most, if not all, fast twitch type muscle cells of the
diaphragm (Fig. 1h). In Ebf3-deﬁcient cells this expression, and
thereby the vast majority of overall Atp2a1 expression, was
reduced to undetectable levels, whereas a minor level among
Ebf3-b-gal-negative cells remained unchanged, indicating a cell-
autonomous defect. As expected, Ebf3 expression was reduced to
background levels in Ebf3-deﬁcient cells (Fig. 3G).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4793
4 NATURE COMMUNICATIONS | 5:3793 | DOI: 10.1038/ncomms4793 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
To evaluate whether compensatory mechanisms are active, or
whether other members of the Atp2a gene family are also
affected by the deletion of Ebf3, we analysed the diaphragms
of E18.5 mice as described29. Loss of Ebf3 reduced not only
Atp2a1a and Atp2a1b, the two isoforms of Atp2a1, but
also Atp2a2 by a factor of 7.5 and its two isoforms Atp2a2a
and Atp2a2b by a factor of 73 and 14, respectively
(Supplementary Fig. 6E). Conversely, Atp2a3, the third gene of
this family, showed a slight but signiﬁcant upregulation in
absence of Ebf3 (Supplementary Fig. 6E). Taken together, loss of
Ebf3 leads to a decrease in the expression of the Atp2a1 and
Atp2a2 genes and their isoforms, whereas Atp2a3 shows a minor
upregulation. The product of the Atp2a1 gene is the Serca1
protein, which has a size of 110 kDa. In Ebf3-deﬁcient
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Figure 2 | Deletion of Ebf3 leads to respiratory failure, postnatal death and alterations in muscle morphology. (a) Frequencies of Ebf3 wild-type
and mutant genotypes before and after birth. No Ebf3-deﬁcient mice can be detected 12 h after birth; E18.5: n¼415, D0.5: n¼ 58. (b) Comparison of
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(c–e) Histological analysis of longitudinal sections of the lung of wild-type (upper row) and Ebf3-deﬁcient (lower row) newborn mice stained with
haematoxylin/eosin. d and e are increasing magniﬁcations as indicated by the insets. Bar, c: 200mm; d: 100mm; e: 50mm. (f) Alcian blue/alizarin red
staining of cartilage and bone of wild-type or Ebf3 / skeletons at E18.5. (g,h) Cross-sections of diaphragm muscle ﬁbres of newborn wild-type
(g) or Ebf3-deﬁcient (h) mice stained with haematoxylin/eosin. Lower panels are higher magniﬁcations as indicated by the inset in the upper panels.
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length in the diaphragm of Ebf3þ /þ , Ebf3þ / and Ebf3 / newborn mice. n¼ 3; error bars¼ s.d.; *Po0.05. (D,E) Single twitch stimulation (50V, 1ms)
of diaphragm muscle from newborn mice of the indicated genotypes. (D) Measurement of single twitch normalized to the cross-sectional area,
representing muscle force in response to the stimulation. (E) Total duration of muscle contraction after single twitch stimulation. n¼ 5 Ebf3þ /þ ,
n¼ 7 Ebf3þ / , n¼4 Ebf3 / ; error bars¼ s.d.; *Po0.05, **Po0.01, ***Po0.001. (F) Ebf3-b-gal-expressing cells were isolated from the diaphragm
of E18.5 Ebf3þ / embryos by ﬂow cytometry and analysed for the expression of the indicated genes by qPCR. Expression in Ebf3þ / cells was set to 1
and relative expression in Ebf3 / cells is shown. n¼ 3, *Po0.05, **Po0.01. (G) Cells of the diaphragm of E18.5 animals were sorted as positive or
negative for the expression of Ebf3-b-gal and analysed by quantitative PCR for the expression of Ebf3 and Atp2a1. Unsorted cells of wild-type diaphragm
were used as control and set to 1; n¼ 3, *Po0.05, **Po0.01. (H) Representative western blot analysis of Serca1 expression in skeletal muscle (SM)
and diaphragm (D) of E18.5 embryos of the indicated genotypes; n¼ 3. In all PCR experiments, values are normalized to wild-type levels, error bars
represent s.d., and P-values were calculated in comparison to the wild-type control.
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diaphragm, the protein was barely detectable and thus strongly
reduced in comparison with wild-type levels (Fig. 3H).
Quantiﬁcation of the protein levels indicated a reduction of
Serca1 in Ebf3-deﬁcient diaphragm by a factor of 3.2. In contrast,
Serca1 from skeletal muscle did not show a signiﬁcant reduction
in Ebf3 / diaphragm compared with Ebf3þ /þ .
Atp2a1 rescues Ebf3-dependent respiratory failure. Since
Ebf3 / mice phenocopy Atp2a1-deﬁcient mice and the
expression of Atp2a1 is strongly downregulated in the absence of
Ebf3, we wanted to determine the importance of Atp2a1 as a
downstream target of Ebf3. Transgenic animals expressing
Atp2a1 under the control of the skeletal muscle-
speciﬁc skeletal a-actin promoter have been reported30. These
mice show transgenic expression in skeletal muscles including the
diaphragm, but do not have any overt phenotype on their own,
allowing us to genetically assess the biological relevance of
Atp2a1 as an Ebf3 target gene in vivo. Genotyping of litters from
Ebf3þ / /Atp2a1tg double-heterozygous crossings revealed a 50%
distribution of the Atp2a1 transgene as expected (Fig. 4a) from
the breeding scheme (Supplementary Fig. 7). Among the Atp2a1
wild-type animals, the frequency of Ebf3þ /þ , Ebf3þ / and
Ebf3 / corresponds to the frequency observed previously
before and after birth (Fig. 4a, left panel). In the presence of the
Atp2a1 transgene, the ratio of Ebf3 / mice at E18.5
surprisingly is not 12.5% as would be expected as a normal
Mendelian ratio but 3%, indicating either a genetic interference
between Ebf3 and the Atp2a1transgene or a synthetic phenotype
(Fig. 4a, right panel). We killed mice at stages E12.5 to E16.5, but
did not observe a higher percentage of the compound Ebf3 / /
Atp2a1tg genotype, arguing against a synthetic phenotype.
A defect earlier than E12.5 seems highly unlikely as the skeletal
a-actin promoter is not active at these stages. The genomic
insertion locus of the Atp2a1 transgene is unknown, but we think
the most likely explanation for the low frequency is genetic
linkage, that is, the transgene is on the same chromosome as Ebf3.
Strikingly, we observe the same frequency of Ebf3 / /Atp2a1tg
animals at D0.5, clearly distinguishing them from Ebf3 / mice.
Ebf3 / /Atp2a1tg mice do not show any signs of cyanosis
or gasping respiration, but display normal morphology and
movement at D0.5 (Fig. 4b). To determine the level of functional
rescue exactly, we analysed sarcomere length in muscle ﬁbres of
the diaphragm from Ebf3þ /þ /Atp2a1tg and Ebf3 / /Atp2a1tg
mice and found no signiﬁcant difference (Fig. 4c). Furthermore,
we subjected whole diaphragms to deﬁned electrical stimulation
as described for the single deletion of Ebf3. Single twitch
stimulation (50V, 1ms) induced a force from Ebf3-deﬁcient
diaphragms that was comparable to Ebf3-expressing muscle
(Fig. 4d). In addition, the duration of contraction was also
comparable in the diaphragm from Ebf3þ /þ /Atp2a1tg and
Ebf3þ /þ /Atp2a1tg mice (Fig. 4e). The force produced under
tetanus stimulation (50V, 1ms, 120Hz for 500ms) was also
rescued by the transgenic expression of Atp2a1 (Supplementary
Fig. 6C) just as the duration of contraction (Supplementary
Fig. 6D). Therefore, we conclude that Atp2a1 is the critical target
gene downstream of Ebf3 causing the defects in muscle relaxation
and the associated cyanotic appearance and postnatal lethality.
However, the transgenic expression of Atp2a1 did not allow for
prolonged survival of Ebf3-deﬁcient mice. In a time period from
24 h after birth up to 4 days, all double-mutant mice died,
but again did not display a cyanotic appearance (Fig. 4f). As
Ebf3 / /Atp2a1tg mice seemed slightly weaker and less active
over time than their littermates, we determined their weight and
found that the gain in newborn mice, particularly from postnatal
day 3 on, is not achieved by Ebf3 / /Atp2a1tg mice (Fig. 4g).
Taken together, the data show that skeletal muscle-speciﬁc
expression of Atp2a1 rescues the defect in muscle relaxation of
the diaphragm, but is unable to compensate for all defects
associated with loss of Ebf3.
Atp2a1 is a direct target gene of Ebf3. The biological importance
of Atp2a1 downstream of Ebf3 and its downregulation in absence
of this transcription factor prompted us to investigate a potential
direct molecular link. Atp2a1 maps to mouse chromosome 7
(ref. 31), and analysis of DNA sequence upstream of the
transcriptional initiation site32 reveals four potential binding
sites for Ebf proteins in its promoter/enhancer (Fig. 5a). Two of
these possess exactly the same DNA sequence as the Ebf-binding
site in the mb-1 promoter where Ebf1 was ﬁrst identiﬁed33;
therefore, we named them as M1 and M2, and two sites as E1 and
E2, which have the inner palindrome of the ideal consensus site
for Ebf proteins34. Ebf3 bound with high afﬁnity to the M1 and
E2 sites but only weakly to the E1 site as shown by electrophoretic
mobility shift assay (EMSA; Fig. 5b). Ebf3 also bound to the M2
site, but slightly different conditions used for the binding buffer
prevent a direct comparison. The binding is speciﬁc, as single-
nucleotide mutation abolished it (the mutant versions are
indicated in Fig. 5a), and the addition of unlabelled (cold)
oligonucleotides in 10-fold excess also leads to a loss of binding
activity. Furthermore, the binding activity could be super-shifted
by an a-ﬂag antibody, demonstrating complex formation between
Ebf3 and the indicated oligonucleotides (Fig. 5b). ChIP assay
using protein extracts from C2C12 cells expressing ﬂag-tagged
Ebf3 showed binding to sites M1, E2 and M2, but not to E1,
largely corresponding to the data from the EMSA assay (Fig. 5c)
and conﬁrming the binding of Ebf3 to these promoter sites
in vivo. To determine whether Ebf3 can transactivate from the
Atp2a1 promoter via the identiﬁed Ebf3-binding sites, a DNA
fragment containing over 1 kb of its promoter was cloned into a
luciferase reporter construct, and point mutations as indicated in
Fig. 5a were introduced into the Ebf-binding sites either alone or
in combination. Figure 5d shows that Ebf3 can transactivate from
the Atp2a1 promoter fragment 4.2-fold. Mutation of site M2
almost completely abolished transactivation, whereas mutation of
site E1 did not have any inﬂuence. Mutation of site M1 or E2 gave
intermediary results. Therefore, we conclude that site M2, which
is closest to the transcriptional start site, is most important for
transactivation of Atp2a1 by Ebf3, and that sites M1 and E2
contribute to reach full activity. Site E1 seems dispensable as Ebf3
binds with low afﬁnity in EMSA, no binding is detected in ChIP
assay and transactivation is not inﬂuenced by its mutation. In
fact, site E1 or neighbouring sequences might negatively inﬂuence
transactivation, as its deletion together with M1 or E2 results in
diminished loss of transactivation (Fig. 5d). Finally, to determine
whether Ebf3 is not only required but also sufﬁcient for the
expression of Atp2a1, C2C12 cells were transfected with Ebf3 and
cultivated in the presence or absence of horse serum to induce
myoblast differentiation. Within 2 days, horse serum alone did
not induce the expression of Atp2a1 (Fig. 5e). Ebf3 alone also had
no effect, but in combination with horse serum leads to a strong
upregulation of Atp2a1. After 5 days, Ebf3 had again no effect on
the expression of Atp2a1, and horse serum had a small inductive
effect, but together, horse serum and Ebf3 strongly induced the
expression of Atp2a1. These data suggest that Ebf3 alone is not
sufﬁcient to induce the expression of endogenous Atp2a1, but
likely acts in concert with other factors expressed during myoblast
differentiation.
Ebf3 and MyoD synergistically induce expression of Atp2a1.
Other members of the Ebf protein family cooperate with basic
helix-loop-helix transcription factors in the induction of target
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Figure 4 | Transgenic expression of Atp2a1 rescues Ebf3-dependent respiratory failure. (a) Ebf3-mutant animals were crossed to Atp2a1-transgenic
mice and frequencies of Ebf3 wild-type and mutant genotypes on an Atp2a1 wild-type or transgenic background are shown before and after birth;
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genes, like Ebf1 with E2A in B-cell development35,36. Moreover,
E-boxes, the consensus binding sites for bHLH transcription
factors, are found highly enriched in the vicinity of Ebf-binding
sites37,38. A detailed examination of the Atp2a1 promoter yielded
ﬁve E-boxes within the Atp2a1 promoter fragment (X1–X5,
Fig. 6a). MyoD and Myf5 are two bHLH transcription factors
binding to E-boxes that are important for myogenic
differentiation. ChIP-seq analysis for both factors during
proliferation and differentiation of primary myoblasts has been
reported and reveals that MyoD binds to two sites in the Atp2a1
promoter during myoblast differentiation, whereas Myf5 does not
bind under both conditions39. We examined binding of MyoD to
E-boxes present in the Atp2a1 promoter by ChIP and could
conﬁrm strong binding to site X1 and weaker but sigiﬁcant
binding also to site X5. Also, sites X3 and X4 gave an increased
signal, but the values did not reach statistical signiﬁcance
(Fig. 6b). In contrast to Ebf3, ChIP-grade antibodies speciﬁc for
MyoD are available, allowing us to examine its binding in
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primary diaphragm cells in the presence and absence of Ebf3.
Figure 6c conﬁrms binding of MyoD to sites X1 and X5 under
wild-type conditions and also shows that MyoD can bind to these
sites in the absence of Ebf3. To analyse the functional importance
of these E-boxes, we tested them individually with wild-type or
mutated sequences together with MyoD. Figure 6d shows that
MyoD can transactivate 3.4-fold from the Atp2a1 promoter,
which is comparable to the induction with Ebf3 alone. Mutation
of the individual E-boxes as indicated in Fig. 6a leads to a
reduction in transactivation potential in case of sites X1 and X5 to
2- and 1.8-fold, respectively, whereas sites X2 to X4 have no
inﬂuence. Combining mutations in sites X1 and X5 leads to a
reduction of transactivation to 1.4-fold (Fig. 6d). To test potential
synergistic effects between Ebf3 and MyoD, we combined these
two factors with reporter constructs used before. Together,
these two transcription factors lead to a 24.4-fold induction
of the Atp2a1 promoter, displaying strong synergy in their
transactivation capacity. Mutation of Ebf-binding sites M1 or M2
in this context results in a reduction of transactivation to 7.6-fold
and 4.8-fold, respectively, and in a reduction to 14.5-fold in case
of site E2 (Fig. 6e). E-boxes X1 and X5 are important for
co-transactivation, as their mutation reduces induction to 6.8-fold
and 4.6-fold. Finally, the combination of the two strongest
mutations for each class of transcription factors, M2 and X5,
reduced the combined transactivation potential of Ebf3 and
MyoD to 2.4-fold (Fig. 6e). As Ebf3 alone is not sufﬁcient to
induce the expression of endogenous Atp2a1 in C2C12 cells
within 2 to 5 days, but can do so in combination with horse
serum (Fig. 5f), we tested whether Ebf3 and MyoD together have
this ability. MyoD alone can induce the expression of Atp2a1
3.2-fold and 2.8-fold after 2 and 5 days, whereas expression of
Ebf3 alone does not signiﬁcantly induce Atp2a1. Together,
however, Ebf3 and MyoD have the potential to strongly induce
the expression of Atp2a1 by 74.6-fold and 53.4-fold after 2 and 5
days post-transfection (Fig. 6f). The synergistic activity between
Ebf3 and MyoD prompted us to investigate a potential direct
interaction between these transcription factors. To this end, we
transfected C2C12 cells with tagged versions of both factors,
and tried co-immunoprecipitation under various conditions, but
failed to detect a direct interaction.
Redundancy between Ebf factors in the induction of Atp2a1.
The ﬁnding that deﬁciency for Ebf3 leads to a downregulation of
Serca1 in the diaphragm, but not in skeletal muscle, (Fig. 3h) is
surprising and indicates that either the regulation of Atp2a1
expression is different between these muscle types or that com-
pensation between Ebf proteins is going on. As mentioned in the
introduction, Ebf3 is part of a highly homologous family of
proteins consisting of four members, of which functional
redundancy has already been demonstrated16. To analyse whether
the mechanism described here might be more general and not
restricted to the diaphragm, we isolated RNA from diaphragm
and skeletal muscle of wild-type mice and determined the
expression of all four Ebf genes by qPCR. Ebf3 shows the
strongest expression in the diaphragm, followed by an
approximately threefold lower expression of Ebf1, whereas Ebf2
and Ebf4 are only weakly expressed (Fig. 7a). In contrast, Ebf1 is
the most strongly expressed family member in the skeletal
muscle, Ebf3 is 3.4-fold lower, and Ebf2 and Ebf4 again are only
weakly expressed (Fig. 7b). To determine whether there is
functional redundancy between the individual Ebf factors in the
induction of the Atp2a1 gene, we ﬁrst tested their ability to
transactivate from the Atp2a1 promoter. In reporter assays Ebf1,
Ebf2 and Ebf4 have a transactivation potential that is comparable
to the activity of Ebf3 (Figs 5d and 7c), indicating potential
redundancy between these factors. To test this ability with the
endogenous gene, we ectopically expressed Ebf factors either
alone or in combination with MyoD in C2C12 cells and
determined the expression of endogenous Atp2a1 after 2 days.
Ebf1, Ebf2 and Ebf4 alone can induce the expression of Atp2a1
approximately two- to threefold, again largely recapitulating the
ability of Ebf3 alone. In combination with MyoD, however, all Ebf
factors show a strong synergistic effect, resulting in a 60- to
80-fold induction of Atp2a1 (Fig. 7d). To test these results also
genetically, we examined the expression of Atp2a1 in skeletal
muscle from Ebf1 wild-type and mutant mice. Loss of one allele
of Ebf1 leads to a downregulation of Atp2a1 by 21%, whereas its
complete deletion reduces Atp2a1 by 51% (Fig. 7e), conﬁrming a
more general role for Ebf proteins in its regulation and also
indicating dose-dependency of Ebf factors in the induction of the
Atp2a1 gene.
Taken together, the data show that Ebf3 is necessary for the
relaxation of the diaphragm by binding to three consensus sites in
the promoter/enhancer of the Atp2a1 gene, where it synergises
with MyoD to induce the expression of Serca1, which is necessary
for Ca2þ -uptake into the sarcoplasmic reticulum (Fig. 7f). This
mechanism, however, is not restricted to Ebf3 and the diaphragm
but general in muscle cells as all Ebf factors can synergise
with MyoD and transactivate from the Atp2a1 promoter. An
overlapping, but also distinct expression pattern, between mostly
Ebf1 and Ebf3 in the diaphragm versus the skeletal muscle is
responsible for biological effects.
Discussion
The transcription factor Ebf3 was originally identiﬁed because of
its expression in the olfactory epithelium and neuronal cells18,19,
and Ebf3-deﬁcient mice have defects in olfactory receptor neuron
projection16. However, Ebf3 is also expressed outside of the
neural system and Ebf3 / mice die immediately after birth, but
only very little is known about its role in other tissues. Here, we
identify respiratory failure caused by the inability of the lung to
unfold at birth as the reason for the postnatal death. Multiple
organs might account for such a phenotype, including the lung,
the rib cage and the muscles involved in respiration, that is,
mainly the diaphragm and the heart. Ebf3 is not expressed in the
lung and the heart, and development of the lung, heart and bone
proceeds normally in the absence of Ebf3. However, Ebf3 is
expressed strongly in the diaphragm, suggesting an involvement
of muscle cells in the Ebf3-dependent respiratory failure.
Consistent with this notion, the function of Ebf3-deﬁcient
muscle cells of the diaphragm is impaired, resulting in less
force produced in response to single or persistent stimulation and
prolonged duration of muscle contraction after stimulation. This
phenotype of impaired muscle relaxation is highly reminiscent of
the deletion of Atp2a1, which encodes for a Ca2þ -ATPase that
catalyses the ATP-dependent transport of Ca2þ from the cytosol
to the lumen of the sarcoplasmic reticulum40. Interestingly,
Serca1 is strongly downregulated in the diaphragm but not in
skeletal muscle of Ebf3-deﬁcient mice. Ebf1, a highly homologous
member of this family of transcription factors, is most strongly
expressed in skeletal muscle. Ebf1 can act via the same binding
sites in the Atp2a1 promoter, synergises with MyoD, and loss of
Ebf1 leads to a downregulation of Atp2a1 expression in skeletal
muscle, indicating redundancy between individual Ebf factors.
It is an interesting question why the diaphragm differs in its
expression of Ebf factors from other skeletal muscles, however, as
the promoters of Ebf genes have not been characterized with the
exception of Ebf1, this remains subject for further study. An
important question is also why there is a downregulation of
Atp2a1 in the absence of Ebf3 since Ebf1 is expressed in the
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diaphragm as well and is also able to induce its expression. Ebf
factors have dose-dependent effects in other cellular contexts like
B-cell and neuronal development16,35 and, in fact, deletion of
only one allele of Ebf1 also leads to a slight reduction of Atp2a1
in skeletal muscle. Therefore, dose dependency seems to be
responsible for this effect.
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Figure 7 | Overlapping expression and redundancy between Ebf genes. (a) Expression of Ebf factors as indicated in the diaphragm from E18.5 embryos
determined by quantitative PCR. Ba/F3 cells were used as negative control (n.c.). n¼ 3, error bars¼ s.d., **Po0.01, ***Po0.001. (b) Same as a,
but skeletal muscle from adult mice was used for analysis. n¼ 3, error bars¼ s.d., **Po0.01, ***Po0.001. (c) Analysis of the transactivation potential
of Ebf factors from the Atp2a1 promoter. HEK293T cells were transfected with reporter plasmids comprising all four Ebf consensus sites in wild-type
form as in Fig. 7d. Ebf1, Ebf2 and Ebf4 in pCMV were co-transfected as activators as indicated. Transfections of the empty pCMV plasmid were set to 1,
and all other values are given accordingly. n¼ 3, error bars¼ s.d., ***Po0.001, P-values are in comparison with mock control of the respective reporter.
(d) Analysis of the expression of Atp2a1 in C2C12 cells by qPCR in response to ectopic expression of Ebf1, Ebf2, Ebf4 and MyoD as indicated 2 days
after transfection. n¼ 3, error bars¼ s.d., *Po0.05, **Po0.01, ***Po0.001. (e) Expression of Atp2a1 determined by qPCR from skeletal muscle of
Ebf1þ /þ , Ebf1þ / and Ebf1 / mice (E18.5); n¼ 3, error bars¼ s.d., *Po0.05, **Po0.01. (f) Model for the role of Ebf factors in muscle physiology.
Ebf (orange ovals) and MyoD (green ovals) directly bind to consensus sequences present in the promoter of the Atp2a1 gene and synergistically
transactivate the expression of Atp2a1. Serca1 mediates Ca2þ re-uptake and muscle relaxation, which are defective in absence of Ebf3.
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The large phenotypic overlap between loss of Ebf3 and Atp2a1
is striking and together with its downregulation already indicates
the potential importance of Atp2a1 as a target gene of Ebf3.
The genetic rescue of Ebf3-dependent muscle relaxation and
respiratory failure by ectopic expression of Atp2a1 in vivo
identiﬁes it as the biologically most relevant downstream target of
Ebf3 in the diaphragm. However, Serca1 does not completely
rescue deﬁciency for Ebf3 as mice die within 4 days after birth.
This is likely the result of a complex situation in the compound
Ebf3/Atp2a1 mutant animals. The skeletal a-actin promoter does
not recapitulate the expression pattern of the endogenous Atp2a1
promoter, and in addition the expression of Atp2a2 is strongly
downregulated. We failed to identify Ebf-binding sites in the
promoter/enhancer of the Atp2a2 gene, and ectopic expression of
Ebf3 and MyoD alone or in combination did not alter Atp2a2
expression levels in C2C12 cells. In addition, since Atp2a2 is
expressed in slow twitch ﬁbres, its downregulation seems to be
indirect. As this situation is not only complex, but due to the
expression of the transgene to some degree also artiﬁcial, we
decided not to follow the synthetic phenotype any further.
Therefore, the analysis of the biological role of Ebf3 after birth
awaits the generation of conditional knock-out mice.
Interestingly, many muscle-speciﬁc genes harbour E-boxes in
their promoter, which act as binding sites for MRF proteins4,7.
However, E-boxes are not tissue-speciﬁc as they occur not only in
muscle-speciﬁc genes, but also have a much broader distribution,
and MRF factors bind to many E-boxes in nonmuscle-speciﬁc
promoters8. Consequently, an important question in muscle
development is how speciﬁcity is achieved. A combinatorial
action between MRF and other transcription factors has been
suggested, and a few examples have been identiﬁed10,41. In B-cell
development, Ebf1 acts synergistically with the transcription
factor E47, a product of the E2A gene, which also binds to
E-boxes35. Although no direct interaction could be demonstrated
so far, they cooperate in the induction of B-cell-speciﬁc genes36.
There are several striking parallels to the data presented here, like
the involvement of Ebf factors and E-box binding proteins, direct
binding to neighbouring sites in the promoter, no detectable
physical interaction but cooperation in the induction of the
downstream gene. Furthermore, MyoD can replace products of
the E2A gene in the synergistic induction of the B-cell-speciﬁc
lambda5 gene, demonstrating redundancy between bHLH
transcription factors in the cooperation with Ebf proteins42.
Therefore, synergistic effects between E-box-binding factors and
Ebf proteins seem to be a broader phenomenon and not restricted
to B cells. Consequently, although Ebf3 just as other Ebf factors is
clearly not muscle speciﬁc, it could be part of a transcriptional
module that together mediates muscle-speciﬁc gene expression.
In parallel to the high conservation of Ebf genes at the sequence
level during evolution13,14,43, there seems to be also a
considerable level of conservation of their biological role.
Collier, the only Ebf gene in Drosophila, is expressed by cells
that support immature haemocytes and is necessary to maintain
this pool of progenitor cells44. This is highly reminiscent of Ebf2
and its role in the support of immature haematopoietic stem and
progenitor cells45. Besides the support of haemocytes, collier is
also required for the formation of the dorsal/acute 3 (DA3)
embryonic muscle, which does not develop in its absence46,47.
Together with nautilus, the only homologue of MRF bHLH
factors in Drosophila, collier controls shape and morphology of
the DA3 muscle48. Here we report that Ebf3 is required for the
relaxation of the diaphragm and that it synergises with MyoD in
inducing a critical cell-type speciﬁc gene. To our knowledge this is
the ﬁrst implication of Ebf genes in muscle cell function in
mammals, but the phenotype described here differs considerably
from the loss of collier in Drosophila. Hence, either the
requirement for Ebf factors has changed during evolution or
the expression of other Ebf family members and redundancy
might mask a broader role for this gene family in muscle
development. Indeed, it was recently shown that Ebf proteins
participate in transcriptional regulation of muscle development in
Xenopus49, favouring the second possibility.
In parallel to a strong evolutionary conservation at the
sequence level, there might be also a conservation at the level
of interaction partners like bHLH transcription factors. Although
collier and Ebf3 are required for development and function of a
speciﬁc muscle, such a conservation seems true at the broad
biological level, but not in detailed aspects. The diaphragm is a
derivative of myoblasts from myotomes C3, C4 and C5, which
migrate into the septum transversum, a condensation of
mesenchymal cells pre-ﬁguring large parts of the diaphragm,
where they expand and differentiate. This process is not
homologous to the generation of the DA3 muscle, but it is
tempting to speculate that a conservation in the speciﬁcation of
muscle identity might exist at the molecular level despite different
organ development at the cellular level. Therefore, rather than
postulating a relationship between the DA3 muscle in Drosophila
and the diaphragm in the mouse, it seems more likely that Ebf
factors probably in combination with the E-box-binding MRF
factors form a module in muscle cell differentiation that has been
adopted during evolution.
Brody’s disease is a rare myopathy, characterized by
exercise-induced impairment of skeletal muscle relaxation,
stiffness and cramps, resulting from impaired Ca2þ -uptake and
Ca2þ -ATPase activity50. Mutations of Atp2a1 were found in 50%
of Brody’s patients and are genetically associated with Brody
disease51. The reason for the remaining cases of Brody myopathy
is unclear, as the genomic sequence of Atp2a1 is unchanged.
Among these, cases have been reported in which the expression of
Serca1 is strongly reduced52. As Serca1 is strongly downregulated
and barely detectable in the diaphragm of Ebf3-deﬁcient mice, we
suggest that Ebf3 might be involved in at least a subgroup of the
remaining cases of Brody disease. This might be either via
mutation of Ebf3 itself, but this is the more unlikely possibility as
the broad expression of Ebf3 will probably result in more defects
after birth. Alternatively, binding sites for Ebf proteins might be
mutated, preventing Ebf3 from transactivating from the human
Atp2a1 promoter.
Methods
Generation of mice. Two DNA fragments corresponding to the Ebf3 genomic
region were isolated from a mouse 129/Ola genomic cosmid library. The ﬁrst
fragment (50-region) expanded 4.85 kb from a PmlI site upstream of the Ebf3
coding region to the translation start codon. The second region was a PstI fragment
of 4.6 kb from intron 4 to intron 6. The targeting construct was obtained by cloning
these fragments in the pBluescript KS vector, followed by insertion of an NLS-lacZ
gene and a PGK::Neo cassette ﬂanked by loxP sites between both fragments.
NLS-LacZ was cloned in frame with the Ebf3 translation start codon. Mouse ES
cells were electroporated with this construct, and colonies were isolated in the
presence of 400 mgml 1 G418. For DNA extraction, cells were digested with
100 mgml 1 Proteinase K in the presence of 50mM Tris-HCl pH 7.5, 100mM
NaCl and 10% SDS. DNA was ethanol precipitated and analysed by Southern
Blot53. Two clones (#1 and #2) out of the 800 clones analysed had correctly
incorporated the targeting construct, as established by Southern blot. Both clones
were injected into C57BL/6 blastocysts that were implanted into pseudopregnant
females. Chimeric mice were bred to obtain germline transmission. Two male
chimera (80%) corresponding to clone #1 were selected to get heterozygous mice.
The PGK::Neo cassette was removed by crossing with PGK-Cre transgenic mice54.
Mutant mice were backcrossed with C57Bl/6 wild-type mice for more than 10
generations. All experiments involving animals were designed in agreement with
the stipulations of the animal care committee of the Helmholtz Zentrum Mu¨nchen
and the ‘Regierung von Oberbayern’.
Genotyping. For genotyping of mice tails were digested for at least 1 h in lysis
buffer (FirePol buffer B (Solis BioDyne), 1.25mM MgCl2, 50 mgml 1 proteinase
K) at 55 C and inactivated for 15min at 95 C. PCR was carried out with genomic
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DNA and 20 pmol of each primer (Ebf3 fwd 50-GGGCACACCACAGTCTGTC-30 ,
Ebf3 wt rev 50-GGAGGATATACAGGGTCACAC-30 , Ebf-lacZ rev 50-GCGCCG
GTCACCATTACC-30) using FirePol (Solis BioDyne) under these conditions:
35 cycles of 94 C for 30 s, 61 C for 1min, 72 C for 30 s. Atp2a1-transgenic mice
were obtained from Jeffery Molkentin (University of Cincinnati, USA) and
genotyped as described30.
Isolation of primary cells. Bone marrow cells were isolated as described55. For
isolating bone marrow cells, bones (two tibia and two femurs per mouse) from
embryos at day E18.5, bones were pre-digested in DMEM supplemented with 0.1%
collagenase (Sigma) and 0.2% dispase (Roche) twice for 20min. After washing with
PBS, bones were cut and digested three times as above, and supernatant was
collected. For cell isolation from whole organs, adult or embryonic mice were
killed, organs removed and detached by a 100-mm cell strainer. Diaphragm cells
were digested in DMEM supplemented with 0.2% collagenase for 30min,
fractionated and resuspended.
Electrophysiology and force measurements. Experiments were conducted on
diaphragm muscle strips from newborn mice. The pups were killed by cervical
dislocation and after the laparotomy, the rib cage containing the whole diaphragm
was excised and kept in cold MEM-Glutamax (Gibco) supplemented with fetal
bovine serum for dissection. A strip from the right ventral costal hemi-diaphragm
was excised keeping both insertions from ribs and central tendon intact. The
muscle strips were horizontally mounted in Ringer-Krebs-Henseleit solution
(140mM NaCl, 5mM KCl, 1.2mM KH2PO4, 1.2mM MgCl2, 2mM CaCl2, 20mM
Hepes, 6mM glucose; pH 7.4; osmolarity between 290–315mOsM). At constant
perfusion, the solution was kept at 25 C and bubbled with gas mixture of 95% O2
and 5% CO2. The costal end was held in a stationary end and the central tendon
attached to the force transducer (SI-H Force Transducer, 0–50mN, SI-KG4, WPI).
The optimal length (Lo) was deﬁned as the muscle length at which twitch tension
development was maximal, corresponding to the apex of the length-active tension
curve. Stimulation was applied using a Grass stimulator SD9 (Grass Instruments,
Quincy, MA) via closely ﬂanking platinum wire electrodes. Supramaximal stimu-
lation during single twitch was reached at 50V, with 1ms squared pulse duration.
Duration of tetanus stimulation was set for 500ms. The diaphragm force-frequency
relationship was assessed at supramaximal stimulation by sequential excitation of
muscles at 50V with pulse duration of 1ms at 1, 5, 10, 15, 30, 60, 90, 120, 150 and
180Hz, during 500ms, every 3min. The cross-sectional area (CSA) of the muscle
strip was calculated by dividing the mass of the muscle (without rib bone and
central tendon; mg) by the product of the optimal length (Lo, mm) and muscle
density (1.056 g cm 3). The tension was calculated as force (mN) per CSA (cm2).
The traces were acquired at 4 KB s 1 and analysed using PowerLab and
LabChart 7.0 (AD Instruments, Australia).
Cell Culture. 70Z/3, 18-81 TKþ and Ba/F3 cells were cultured in RPMI 1640,
supplemented with 10% fetal calf serum (FCS; PAA), 1% penicillin and strepto-
mycin, 1% L-glutamine. For 70/Z3 and 18-81 TKþ , 1% sodium pyruvate and
0.003% b-mercaptoethanol was used additionally. For the maintenance of Ba/F3
cells, the culture medium was supplemented in addition with 10% conditioned
medium from WEHI3 cells as a source of IL-3. WEHI-3B and Whitlock-Witte
cultures were propagated in RPMI 1640 supplemented with 10% FCS and 0.0003%
b-mercaptoethanol. Stromal cell lines (2018, AFT024, C2C12, GPþE86, HEK293T)
were grown in Dulbecco’s modiﬁed Eagle medium with Glutamax (DMEM), and
osteoblastic cells (C3H10T½, MC3T3) were cultured in minimum essential
medium (MEMalpha) with in addition supplemented 10% FCS, penicillin and
streptomycin and L-Glutamine. All reagents described were purchased from Gibco
unless stated otherwise. In vitro differentiation assay was performed as described56.
In brief, C2C12 cells were transfected with Ebf3-expressing plasmid, and in vitro
differentiation was initiated by adding 2% horse serum in medium instead of fetal
calf serum for 2 or 5 days.
CFU-F assay. Mouse bone marrow cells were harvested from E18.5 Ebf3þ /þ and
Ebf3 / mice as described above. Cell numbers were determined by using Casy
cell counter (Scha¨rfe Systems). Cells were diluted in mouse Complete MesenCult
Medium (StemCell Technologies), and 10,000 cells were seeded per well in six-well
plates. The cells were cultured at 37 C in 5% CO2 for 10 days without medium
change. The medium was aspirated, and each well was washed twice with PBS
thereafter. Cells were ﬁxed with methanol for 10min at room temperature. The
methanol was removed, and each well was stained with Giemsa Staining Solution
for 10min at room temperature. The staining solution was aspirated and each well
was washed with water for several times to remove unbound stain. The water was
removed and the wells were allowed to air dry. Stained colonies were counted
microscopically.
Electron microscopy. Mice were killed at indicated embryonic days. After ﬁxating
whole mice in ﬁxation buffer (2.5% PFA, 2% glutaraldehyde, So¨rens-buffer
(pH 7.4)) for 1 h, further ﬁxation of single organs was carried out in 2.5%
glutaraldehyde at 4 C. Samples were washed three times with cacodylate buffer
(pH 7.4, Science Services) and ﬁxated in chromosmium acid (1.25% potassium
dichromate (K2Cr2O7; pH 7.2), 1% osmium tetroxide (OsO4), 0.85% NaCl).
After stepwise dehydration, samples were treated with propylenoxide (Merck).
Afterwards, samples were incubated in 1:11-mixture (Epon (246mgml 1
dodecenylsuccinic anhydride (Merck), 326mgml 1 methyl-5-norbornene-1,3-
dicarboxylic anhydride (Roth), 522mgml 1 glyicidyl ether 100 (Epon 812, EMS),
15 ml ml 1 2,4,6-tris-dimethylaminomethyl-phenol (Roth) and propylene oxide
(Merck)). Sections were generated using Leica Ultramicrotome and stained with
haematoxylin/eosin or analysed by using a transmission-electron microscope EM
10 CR (Zeiss).
Haematoxylin/eosin staining. Sections were hydrated and afterwards incubated
for at least 4 h in haematoxylin buffer (0.2 g l 1 sodium iodate, 91.8 g l 1
potassium alum sulphate, 50 g l 1 chloralhydrate, 1 g l 1 citric acid, 1 g l 1
hematoxylin; Merck). Following a washing step with water, sections were stained
for 20 s with Eosin (0.17% acid, 0.58% sodium acetate, 5 g l 1 eosin Y; Merck) and
washed again. For mounting, sections were again stepwise dehydrated, incubated
with xylene and embedded with Eukitt (Kindler).
b-Galactosidase staining. Cryosections or whole embryos were perfused in
phosphate buffer (23mM sodium phosphate monobasic, 77mM sodium phosphate
dibasic, pH 7.3). After ﬁxation (0.2% glutaraldehyde, 0.5mM EGTA (pH 7.3),
2mM magnesium chloride, 94mM sodium phosphate (pH 7.3)), samples
were washed three times in wash buffer (625M magnesium chloride, 0.02%
Nonidet-P40, 97.6mM sodium phosphate, pH 7.3). Staining was carried out in
staining solution (96% wash buffer as mentioned above, 4% di-methyl formamide,
10mgml 1 X-gal (Roche), 2.12mg potassium ferrocyanide, 1.64mg potassium
ferricyanide) for at least 16 h. Samples were washed as above, ﬁxed with 4% PFA,
washed twice in PBS and stepwise dehydrated. After incubation in xylene, sections
could be mounted (DPX Mountant, Fluka). All reagents were obtained from Sigma,
if not otherwise provided. Whole mounts were stained as described above, but were
photographed after ﬁxing and washing steps.
Bone histology. Analysis of bone and cartilage by alcian blue/alizarin red staining
was done as described27. In brief, skin of the embryo was removed and whole
embryo was ﬁxed in 95% ethanol for several days. All internal organs were
removed and skeletal tissue was stained for at least 18 h using alcian blue (90%
ethanol, 20% glacial acetic acid, 0.19mgml 1 alcian blue). After washing twice
with 95% ethanol, embryos were macerated in 2% potassium hydroxide. Next,
embryos were stained with Alizarin Red S in 2% KOH solution. After stepwise
dehydration of the embryo in KOH-glycerine solution, skeleton and cartilage were
analysed. To examine calciﬁed bone matrix, femurs and tibia from embryos were
cryosectioned and stained by von Kossa solution as described27.
Flow cytometry. For ﬂow cytometry, cells were obtained from the diaphragm
or the bone marrow as described above. Isolated cells were incubated with
ﬂuorochrome-conjugated antibodies according to standard procedures, measured
or sorted using either a FACSCalibur or a FACSAriaIII (BD Biosciences), and data
were analysed using CELLQuestPro, FACSDiva Software (Becton Dickinson
GmbH) and FlowJo 9.3 (Treestar) software. For depletion of dead cells propidium
iodide was used. Conjugated antibodies directed against the following markers were
obtained from BD Biosciences: Mac1 (M1/70), Gr1 (RB6-8C5), B220 (RA3-6B2)
and CD43 (RM4-5). Antibody CD45.2 (104) was obtained from eBioscience. All
antibodies were used at a dilution of 1:250. For Ebf3-b-galactosidase detection, cells
were isolated as described above, incubated in 1% FCS and 1mM ﬂuorescein
digalactoside (FDG; Invitrogen) for 75 s at 37 C and resuspended in ice-cold DPBS
thereafter.
Gene expression analysis measurement by qPCR. In brief, mRNA was isolated
from cells, whole organs or embryos using peqGOLD TriFast (Peqlab) according to
manufacturer’s instructions; organs and embryos were dispersed before using an
Ultra Turrax T25 (IKA Labortechnik). cDNA was synthesized with a SuperScript II
reverse transcriptase kit (Invitrogen). PCR reactions were performed in duplicate
with SYBR Green I Master in a LightCycler 480II (Roche) with standard condi-
tions: 95 C for 10min followed by 45 cycles of 95 C for 10 s, 65 C for 10 s and
72 C for 10 s. Alternatively, 40 cycles with an annealing temperature of 63 C were
used. Primer sequences for Atp2a1aþ b, Atp2a 2a, Atp2a 2b, Atp2a 1þ 2, Atp2a 2,
Atp2a 3, Sarcolipin and Phospholamban are described29; sequences for MyHC-Ib,
MyHC-IIA, MyHC-IIB, MyHC-IIX/D are according to57, and all other sequences
are listed in the Supplementary Methods. Target gene expression was normalized
to Hypoxanthine phosphoribosyltransferase (HPRT) expression.
Cloning and site-directed mutagenesis. Ebf3 was inserted into the mammalian
expression vector pCMVcyto using standard methods. CTAP-MyoD was obtained
from Michael Rudnicki (University of Ottawa, Canada) as described39. PCR using
speciﬁc primer for genes or genomic DNA were designed with additional
restriction sites as indicated below with italic letters. Subcloning was done by
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digesting PCR products and relevant vectors with corresponding enzymes for at
least 3 h, puriﬁed by gel extraction kit (Qiagen), and ligated for at least 16 h at
16 C. The QuikChange site-directed mutagenesis kit (Stratagene) was used
according to the manufacturer’s instructions to introduce mutations into
Ebf-binding sequences. Primer sequences to generate point mutations are indicated
with small letters given below; binding site core palindromes are underlined.
Sequencing was done for each construct to exclude errors.
Protein extraction and western blotting. Cells or organs were washed twice in
ice-cold PBS and solubilised in the lysis buffer (50mM Tris (pH 8), 150mM NaCl,
1% NP-40, 1 mgml 1 leupeptin, 1 mgml 1 aprotinin, 100mgml 1 PMSF] using
Ultra Turrax T25. The samples were lysed for 40min on ice. The supernatant
(soluble whole-cell lysate) was fractionated on a 10-12% SDS-polyacrylamide
gel and then transferred onto nitrocellulose membranes (Protran, Whatman).
Membranes were ﬁrst blocked in 5% milk-PBS-Tween and then incubated for 14 h
at 4 C with 5% milk-PBS-Tween containing the ﬁrst antibody in a dilution
recommended by the manufacturer. Membranes were washed three times with
PBS-Tween, incubated with 5% milk-PBS-Tween, containing alkaline phosphatase-
conjugated secondary polyclonal antibody, and then washed as mentioned above.
Signals were detected using detection mixture (0.1M Tris-HCl (pH 8.6),
0.25mgml 1 luminol, 0.11mgml 1 para-hydroxy-conmarin acid, 0.009% H2O2)
and Hyperﬁlm ECL (Amersham). The anti-b-Actin (AC-74), a-Flag (M2; F3165),
a-Serca1 (adult; IIH11) and secondary a-mouse-IgG.HRP antibodies were
obtained from Sigma. The anti-b-Tubulin (5H1) was obtained from BD
Pharmingen and a-Serca1 (embryonic; VE121G9) antibody from Thermo
Scientiﬁc. The secondary a-rat-IgGþ IgM.HRP antibody was purchased from
Jackson Immuno Research. Bands in western blot experiments were quantiﬁed
using the open source software ImageJ (http://rsb.info.nih.gov/ij/; W. S. Rasband,
NIH, National Institutes of Health, Bethesda, MD).
Statistics. P-values were determined with the Student’s two-tailed t-test for
independent samples, assuming equal variances on all experimental data sets.
EMSA. Double-stranded oligonucleotides were annealed in annealing buffer
(10mM Tris/HCl (pH 7.4), 10mM MgCl2, 50mM NaCl) and labelled by ﬁlling up
with Klenow enzyme, [a-P32]-dCTP, and unlabelled dATP, dGTP and dTTP and
puriﬁed using Sephadex G50 columns (Amersham Bioscience). The probes used,
are listed below. Probes with mutations (small letters) in Ebf-binding sites
(underlined) were synthesized as shown in Fig. 6a. EMSA was performed as
following: 5 mg protein extracts from HEK293T cells (as described in protein
extraction) was mixed in either binding buffer 1 (10mM HEPES (pH 7.9), 70mM
KCl, 4% glycerol, 1mM EDTA, 1mM DTT, 1 protease-inhibitor (complete mini
EDTA-free, Roche), 2 ml poly(dIdC) (1mgml 1, Sigma), 2 ml BSA (1mgml 1),
2.5mM MgCl2) or for M2-binding site in binding buffer 2 A(20mM HEPES
(pH 7.9), 75mM NaCl, 1% glycerol, 1 mgml 1 salmon sperm DNA, 2mM DTT,
1 protease-inhibitor (complete mini EDTA-free, Roche), 1 ml poly(dIdC)
(1mgml 1, Sigma) 2 ml BSA (1mgml 1), 2mM MgCl2) with either wild-type or
mutated probe DNA (250 ng ml 1), anti-Flag M2 (F3165; Sigma) antibody or
10-fold concentrated unlabelled probe for competition as indicated. Binding
complexes were fractionated on a 4% polyacrylamide gel. After drying of the gel,
signals were detected using Biomax MS ﬁlms (Kodak).
Chromatin Immunoprecipitation. For ChIP assay, either C2C12 cells were
transiently transfected for 2 days or single-cell suspensions of 10 diaphragms
of Ebf3þ /þ and Ebf3 / mice each were pooled, resuspended in IP-Buffer
(10mM Hepes (pH 7.9), 10mM KCl, 1.5mM MgCl2, 0.34M sucrose, 10% protein
inhibitors (complete mini EDTA-free, Roche) in glycerol, 0.1% Triton X-100)
and partially digested in 1,000U Mnase (NEB) for 2min at 37 C. Mnase was
inactivated by adding 10mM EGTA. Afterwards, 150mM KCl and 0.2%
TritonX-100 were added and immunoprecipitation was performed with
a-Flag-coupled magnetic beads (M2; Sigma) or an a-MyoD speciﬁc antibody
(5.8A, Santa Cruz Biotechnology) for at least 16 h at 4 C under rotation. Then
samples were washed twice with washing buffer A (50mM Hepes (pH 7.9),
140mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% Na-deoxycholate, 0.1% SDS)
and twice with washing buffer 2 (washing buffer 1, 500mM NaCl) for 10min.
Precipitated complexes were eluted in elution buffer (50mM Tris (pH 8.0), 1mM
EDTA, 1% SDS), reverse crosslinked by incubation at 65 C for at least 16 h and
puriﬁed using NucleoSpin PCR puriﬁcation kit (Macherey-Nagel). DNA was used
for RT–PCR as indicated above, and oligonucleotides and PCR programme are
listed above. Input samples were ampliﬁed simultaneously to internal controls.
Transient transfections and reporter assay. C2C12 cells were transfected by
Lipofectamine 2000 (Invitrogen) as described in manufacturer’s protocol with a 1:3
ratio of DNA (mg) and Lipofectamine (ml). HEK293T cells were transfected using
polyethylenimine (PEI, 1mgml 1; Sigma) according to the standard conditions
with a 1:1 ratio of DNA (mg) and PEI (ml). For reporter assays, HEK293T cells were
transfected with 5 mg of plasmid DNA (composed of reporter/luciferase
(pCMVcyto), activator (pBLLuc5) and b-Galactosidase (pCMVlacZ) plasmids;
5:10:1). Cells were harvested in 100ml reporter lysis buffer (10% glycerol, 1%
Triton X-100, 2mM EDTA, 25mM Tris (HCl; pH 7.8), 2mM DTT) 48 h post-
transfection. Measurement of luciferase activity was carried out by adding assay
buffer (20mM tricin, 1.07mM magnesium carbonate pentahydrate, 2.67mM
MgSO4, 33.3mM DTT, 0.1mM EDTA, 530 mM ATP, 270 mM acetyl-coenzyme A,
470 mM D( )-luciferin (Roche), pH 5.8) to the sample duplicates at 560 nm in the
micro-plate luminometer OrionII. b-Galactosidase activity was measured at
475 nm after adding ﬁrst assay buffer (1% Tropix GalactonPlus; Applied
Biosystems, 1mM MgCl2, 100mM Na-P pH 8) and 20min later activation
buffer (0.2M NaOH; 10% Tropix Emerald Enhancer; Applied Biosystems).
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